Analysis of Whole CDR3 TCR Repertoire after Hematopoietic Stem Cell Transplantation in Two Clinical Cohorts
Allogenic hematopoietic stem cell transplant (HSCT) is a potentially curative therapy for bone marrow disorders and cancers. It is the graft-versus-leukemia effect exerted by alloreactive T cells that drives this process. However, a major cause of morbidity in these patients is GVHD, which is when the balance of alloreactive T cells tips too far to attack host cells [1, 2]. Corticosteroids are the first line of therapy but less than 50% of patients achieve a lasting response [3]. Patients non-responsive to steroids require additional therapies with little to no benefit.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: O. Shah, J.S. Tamaresis, L.J. Kenyon, L. Xu, P. Zheng, P. Gupta, K. RangarajanK, S. Lee, S. Spellman, S. Nikiforow, J. Zehnder, E.H. Meyer Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Corticosteroid Therapy | Hematology | Leukemia | Stem Cell Therapy | Stem Cells | Transplants